Pharmaceutical USA-based Javelin Pharmaceuticals, the subject of a $145 million takeover bid from Hospira, saw its shares plummet 25% to $1.35 in morning trading yesterday after it revealed that Therabel Pharma UK, a subsidiary of Netherlands-headquartered Therabel Pharma NV and Javelin's licensee for commercial rights to the non-steroidal anti-inflammatory drug (NSAID) Dyloject (diclofenac sodium) in injectable form in the European Union, publicly announced that it is voluntarily withdrawing all batches of the drug from the UK market with a Drug Alert Class 2 Medicines Recall. 25 May 2010